Known targets — ChEMBL curated mechanism
PIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5
The experimentally established mechanism targets of Buparlisib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA known ✓ | P42336 | 8/20 | 0.96 |
| ▸ | PIK3R1 known ✓ | P27986 | 4/20 | 0.96 |
| ▸ | PIK3CG known ✓ | P48736 | 3/20 | 0.96 |
| ▸ | PIK3CB known ✓ | P42338 | 3/20 | 0.96 |
| ▸ | PIK3R5 known ✓ | Q8WYR1 | 2/20 | 0.96 |
| ▸ | PIK3CD known ✓ | O00329 | 2/20 | 0.96 |
| ▸ | MTOR | P42345 | 11/20 | 0.96 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.96 |
| ▸ | PRKDC | P78527 | 2/20 | 0.96 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.96 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.96 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.96 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.69 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.69 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.69 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Buparlisib SCHEMBL143412 | 0.99 | MTOR (0.98) | MTORPIK3CAPIK3R1PIK3CGPIK3CB | |
| Buparlisib SCHEMBL29412438 | 0.99 | MTOR (0.98) | MTORPIK3CAPIK3R1PIK3CGPIK3CB | |
| Buparlisib SCHEMBL29493083 | 0.99 | MTOR (0.98) | MTORPIK3CAPIK3R1PIK3CGPIK3CB | |
| Buparlisib SCHEMBL18528952 | 0.99 | MTOR (0.98) | MTORPIK3CAPIK3R1PIK3CGPIK3CB | |
| Buparlisib SCHEMBL896966 | 0.99 | MTOR (0.98) | MTORPIK3CAPIK3R1PIK3CGPIK3CB | |
| Buparlisib SCHEMBL146956 | 0.98 | MTOR (1.00) | MTORPIK3CAPIK3R1PIK3CGPIK3CB | |
| Buparlisib SCHEMBL29387968 | 0.98 | MTOR (1.00) | MTORPIK3CAPIK3R1PIK3CGPIK3CB | |
| Buparlisib SCHEMBL29351351 | 0.98 | MTOR (1.00) | MTORPIK3CAPIK3R1PIK3CGPIK3CB | |
| Buparlisib SCHEMBL29350945 | 0.98 | MTOR (1.00) | MTORPIK3CAPIK3R1PIK3CGPIK3CB | |
| SCHEMBL19460575 | 0.96 | MTOR (0.96) | MTORPIK3CAPIK3R1PIK3CGPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3040333-B1 | CRYSTALLINE FORMS OF 5-(2,6-DI-4-MORPHOLINYL-4-PYRIDMIDINYL)-4-TRIFLUOROMETHYLPYRIDIN-2-AMINE, A PIK3 INHIBITOR | NOVARTIS AG (CH) | 2018-09-12 | — | — | EP | disclosed |
| US-9452994-B2 | Manufacturing process for pyrimidine derivatives | NOVARTIS AG (CH) | 2016-09-27 | — | — | US | disclosed |
| US-20160251334-A1 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | FLUBACHER DIETMAR (DE) | 2016-09-01 | — | — | US | disclosed |
| EP-3040333-A1 | CRYSTALLINE FORMS OF 5-(2,6-DI-4-MORPHOLINYL-4-PYRIDMIDINYL)-4-TRIFLUOROMETHYLPYRIDIN-2-AMINE, A PIK3 INHIBITOR | Novartis AG (CH) | 2016-07-06 | — | — | EP | disclosed |
| US-9359326-B2 | Manufacturing process for pyrimidine derivatives | NOVARTIS AG (CH) | 2016-06-07 | — | — | US | disclosed |
| US-9181215-B2 | Manufacturing process for pyrimidine derivatives | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-20150232446-A1 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-08-20 | — | — | US | disclosed |
| US-20130225571-A1 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2013-08-29 | — | — | US | disclosed |
| EP-2621908-A2 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012044727-A2 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225571-A1 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | UMPS, HPRT1, TYMS | PIK3CA 879/4885PIK3R1 4209/4885PIK3CG 2133/4885 |
| US-20150232446-A1 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | UMPS, HPRT1, NUDT1 | PIK3CA 602/4885PIK3R1 4000/4885PIK3CG 1738/4885 |
| US-20160251334-A1 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | UMPS, HPRT1, NUDT1 | PIK3CA 602/4885PIK3R1 4000/4885PIK3CG 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.